Deray G, Baumelou A, Hornych A, Merdjan H, de Groc F
Eur J Clin Pharmacol. 1986;30(4):499-501. doi: 10.1007/BF00607969.
In 6 healthy subjects the effect of clometacin on renal function, sodium and water excretion, plasma renin activity and urinary excretion of prostaglandins has been studied. After four days of treatment with clometacin, the excretion of urinary prostaglandins E2, F2 alpha and 6 keto F1 alpha and thromboxane B2 were reduced by 61.2, 41.2, 59 and 42%, respectively. 62% reduction in plasma renin activity was also observed. There was no significant change in mean blood pressure, heart rate, body weight, creatinine clearance or urinary excretion of sodium. It is concluded that clometacin is an efficient cyclooxygenase inhibitor in healthy individuals with a normal sodium intake, and that caution is required when giving clometacin to patients at risk of developing renal failure during treatment with a cyclooxygenase inhibitor.
在6名健康受试者中,研究了氯美辛对肾功能、钠和水排泄、血浆肾素活性以及前列腺素尿排泄的影响。用氯美辛治疗4天后,尿前列腺素E2、F2α、6-酮-F1α和血栓素B2的排泄分别减少了61.2%、41.2%、59%和42%。还观察到血浆肾素活性降低了62%。平均血压、心率、体重、肌酐清除率或尿钠排泄均无显著变化。结论是,在钠摄入正常的健康个体中,氯美辛是一种有效的环氧化酶抑制剂,在用环氧化酶抑制剂治疗期间,给有发生肾衰竭风险的患者使用氯美辛时需要谨慎。